Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 2/20 | 0.37 |
| ▸ | CES1 | P23141 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSPB1 | P04792 | 3/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | AGXT | P21549 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL438800 | 0.86 | ALDH1A1 (0.41) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL14884524 | 0.82 | CA3 (0.43) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL2281581 | 0.79 | PPARG (0.38) | — | |
| SCHEMBL7578688 | 0.77 | MAPK1 (0.37) | ALDH1A1KDM1AKDM1B | |
| SCHEMBL17439490 | 0.77 | ACHE (0.41) | CA9ALDH1A1NFE2L2 | |
| SCHEMBL2472494 | 0.77 | CA3 (0.43) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL337814 | 0.77 | FFAR1 (0.40) | — | |
| SCHEMBL4469317 | 0.77 | SLC6A4 (0.37) | — | |
| SCHEMBL16634552 | 0.77 | ALDH1A1 (0.48) | ALDH1A1IDO1AGXT | |
| SCHEMBL9487857 | 0.77 | CA3 (0.46) | CA3CA6CA5ACA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103471-A1 | CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV | ASSEMBLY BIOSCIENCES INC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4701627-A1 | ORAL PHARMACEUTICAL COMPOSITIONS | Assembly Biosciences, Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20260014154-A1 | CYCLIC UREA THIAZOLYL COMPOUND FOR TREATMENT OF VIRAL INFECTIONS UNRESPONSIVE TO TREATMENT WITH A FIRST ANTIVIRAL THERAPY | ASSEMBLY BIOSCIENCES INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12522582-B2 | Antiviral indolinyl compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20260001843-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2026-01-01 | — | — | US | disclosed |
| US-20250387397-A1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME LLC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250376478-A1 | CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV | ASSEMBLY BIOSCIENCES INC (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4580601-A1 | PHARMACEUTICAL COMPOSITIONS FOR HERPES VIRUS | Assembly Biosciences, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| EP-4581029-A1 | CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV | Assembly Biosciences, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20250214970-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2025-07-03 | — | — | US | disclosed |
| EP-1224175-B1 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2004-03-17 | — | — | EP | disclosed |
| WO-2004004652-A2 | MITOTIC KINESIN BINDING SITE | MERCK & CO., INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| EP-1379498-A1 | SULPHONES WHICH MODULATE THE ACTION OF GAMMA SECRETASE | MERCK SHARP & DOHME LTD. (GB) | 2004-01-14 | — | — | EP | disclosed |
| WO-2003105855-A1 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003106417-A1 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030092677-A1 | Glutamate receptor antagonists | ADAM GEO (DE) | 2003-05-15 | — | — | US | disclosed |
| US-6509328-B1 | Metabotropic glutamate receptor antagonists and accordingly are useful for the treatment of a range of neurological disorders, including psychosis, schizophrenia, Alzheimer's and others | HOFFMANN-LA ROCHE INC. | 2003-01-21 | — | — | US | disclosed |
| WO-2002081435-A1 | SULPHONES WHICH MODULATE THE ACTION OF GAMMA SECRETASE | MERCK SHARP & DOHME LIMITED (GB) | 2002-10-17 | — | — | WO | disclosed |
| EP-1224175-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001029012-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092677-A1 | Glutamate receptor antagonists | GRM1, GRM3, GRM2 | CA3 945/4885CA6 3485/4885CA5A 3042/4885 |
| US-20260103471-A1 | CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV | TK1, UNG, SMCHD1 | CA3 4344/4885CA6 2773/4885CA5A 3642/4885 |
| US-20260014154-A1 | CYCLIC UREA THIAZOLYL COMPOUND FOR TREATMENT OF VIRAL INFECTIONS UNRESPONSIVE TO TREATMENT WITH A FIRST ANTIVIRAL THERAPY | DNA2, TK1, TYMP | CA3 3703/4885CA6 1435/4885CA5A 3746/4885 |
| US-20260001843-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, NPBWR1 | CA3 952/4885CA6 2823/4885CA5A 3053/4885 |
| US-20250214970-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN3A, SCN2A | CA3 265/4885CA6 2676/4885CA5A 872/4885 |
| US-20250376478-A1 | CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV | TYMP, TK1, TREH | CA3 3491/4885CA6 947/4885CA5A 1349/4885 |
| US-20250387397-A1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | ADORA2A, ADORA2B, ADORA1 | CA3 2996/4885CA6 1906/4885CA5A 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.